Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE

Allspring Global Investments Holdings LLC lessened its stake in Haemonetics Corporation (NYSE:HAE) by 11.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 939,727 shares of the medical instruments supplier’s stock after selling 121,063 shares during the period. Allspring Global Investments Holdings LLC owned approximately 2.01% of Haemonetics worth $75,159,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Central Pacific Bank Trust Division raised its position in Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock valued at $713,000 after purchasing an additional 188 shares in the last quarter. Quantinno Capital Management LP boosted its stake in Haemonetics by 9.0% in the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after buying an additional 289 shares in the last quarter. CWC Advisors LLC. grew its position in Haemonetics by 7.8% during the third quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock valued at $222,000 after acquiring an additional 328 shares during the last quarter. Creative Planning grew its position in Haemonetics by 3.3% during the second quarter. Creative Planning now owns 10,534 shares of the medical instruments supplier’s stock valued at $786,000 after acquiring an additional 335 shares during the last quarter. Finally, True Wealth Design LLC raised its stake in shares of Haemonetics by 6,700.0% during the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HAE shares. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. upped their price target on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Citigroup reduced their price objective on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.89.

Haemonetics Price Performance

HAE stock opened at $56.34 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The firm has a 50-day moving average of $61.65 and a 200 day moving average of $65.09. The company has a market cap of $2.62 billion, a P/E ratio of 15.52, a PEG ratio of 1.15 and a beta of 0.28.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.